Fredun Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 7, 2025, 8:30 pm

Market Cap	318 Cr.
Current Price	674
High / Low	1,024/635
Stock P/E	16.9
Book Value	277
Dividend Yield	0.10 %
ROCE	17.1 %
ROE	14.3 %
Face Value	10.0
PEG Ratio	0.33

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Fredun Pharmaceuticals Ltd

Competitors of Fredun Pharmaceuticals Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	6.71 Cr.	3.51	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/32.1	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	38.0 Cr.	26.0	29.0/8.74	38.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	70.4 Cr.	93.5	155/79.0	11.4	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,255.37 Cr	1,081.84		42.42	185.80	0.37%	16.00%	16.32%	6.27

All Competitor Stocks of Fredun Pharmaceuticals Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	54.23	71.85	48.42	70.32	77.96	79.81	62.05	81.98	87.00	118.03	78.82	107.35	102.70
Expenses	49.88	66.46	44.55	63.52	70.66	67.55	54.44	72.37	76.48	106.87	68.34	93.40	89.48
Operating Profit	4.35	5.39	3.87	6.80	7.30	12.26	7.61	9.61	10.52	11.16	10.48	13.95	13.22
OPM %	8.02%	7.50%	7.99%	9.67%	9.36%	15.36%	12.26%	11.72%	12.09%	9.46%	13.30%	12.99%	12.87%
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest	1.25	1.72	1.91	1.86	1.95	3.55	2.61	2.90	3.77	4.37	3.91	5.31	5.00
Depreciation	0.55	0.58	0.65	0.72	0.74	0.70	0.92	0.94	0.99	0.96	1.05	1.06	1.09
Profit before tax	2.55	3.09	1.31	4.22	4.61	8.01	4.08	5.77	5.76	5.83	5.52	7.58	7.13
Tax %	26.67%	25.57%	27.48%	25.12%	25.16%	51.44%	41.18%	31.72%	26.74%	13.38%	25.18%	43.54%	25.25%
Net Profit	1.87	2.30	0.94	3.15	3.46	3.89	2.40	3.94	4.22	5.06	4.13	4.27	5.33
EPS in Rs	4.22	5.19	2.11	7.07	7.66	8.58	5.24	8.41	8.98	10.76	8.75	9.04	11.29

Last Updated: March 4, 2025, 12:17 pm

Below is a detailed analysis of the quarterly data for Fredun Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹102.70 Cr.. The value appears to be declining and may need further review. It has decreased from 107.35 Cr. (Sep 2024) to ₹102.70 Cr., marking a decrease of 4.65 Cr..
For Expenses, as of Dec 2024, the value is ₹89.48 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 93.40 Cr. (Sep 2024) to ₹89.48 Cr., marking a decrease of 3.92 Cr..
For Operating Profit, as of Dec 2024, the value is ₹13.22 Cr.. The value appears to be declining and may need further review. It has decreased from 13.95 Cr. (Sep 2024) to ₹13.22 Cr., marking a decrease of 0.73 Cr..
For OPM %, as of Dec 2024, the value is 12.87%. The value appears to be declining and may need further review. It has decreased from 12.99% (Sep 2024) to 12.87%, marking a decrease of 0.12%.
For Other Income, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Interest, as of Dec 2024, the value is ₹5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.31 Cr. (Sep 2024) to ₹5.00 Cr., marking a decrease of 0.31 Cr..
For Depreciation, as of Dec 2024, the value is ₹1.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.06 Cr. (Sep 2024) to ₹1.09 Cr., marking an increase of ₹0.03 Cr..
For Profit before tax, as of Dec 2024, the value is ₹7.13 Cr.. The value appears to be declining and may need further review. It has decreased from 7.58 Cr. (Sep 2024) to ₹7.13 Cr., marking a decrease of 0.45 Cr..
For Tax %, as of Dec 2024, the value is 25.25%. The value appears to be improving (decreasing) as expected. It has decreased from 43.54% (Sep 2024) to 25.25%, marking a decrease of 18.29%.
For Net Profit, as of Dec 2024, the value is ₹5.33 Cr.. The value appears strong and on an upward trend. It has increased from 4.27 Cr. (Sep 2024) to ₹5.33 Cr., marking an increase of ₹1.06 Cr..
For EPS in Rs, as of Dec 2024, the value is 11.29. The value appears strong and on an upward trend. It has increased from ₹9.04 (Sep 2024) to 11.29, marking an increase of ₹2.25.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 4:00 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	15	21	25	42	57	60	97	113	134	222	275	348	407
Expenses	14	20	24	38	53	54	87	104	126	208	247	310	358
Operating Profit	1	1	2	4	3	6	10	8	8	14	28	38	49
OPM %	9%	7%	7%	9%	6%	10%	11%	7%	6%	6%	10%	11%	12%
Other Income	0	0	0	1	2	0	0	1	1	2	2	1	0
Interest	1	1	1	2	2	2	3	4	4	5	9	14	19
Depreciation	0	1	1	1	1	1	1	2	2	2	3	4	4
Profit before tax	0	0	1	2	2	3	6	2	3	9	18	21	26
Tax %	80%	47%	52%	42%	36%	34%	28%	24%	37%	26%	38%	27%
Net Profit	0	0	0	1	1	2	4	2	2	6	11	16	19
EPS in Rs	0.04	1.02	1.11	4.55	6.08	5.11	11.18	4.76	5.04	14.30	23.85	33.22	39.84
Dividend Payout %	0%	0%	0%	13%	10%	12%	6%	14%	14%	5%	3%	2%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	0.00%	100.00%	100.00%	-50.00%	0.00%	200.00%	83.33%	45.45%
Change in YoY Net Profit Growth (%)	0.00%	100.00%	0.00%	-150.00%	50.00%	200.00%	-116.67%	-37.88%

Fredun Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	32%
5 Years:	29%
3 Years:	38%
TTM:	31%

Compounded Profit Growth
10 Years:	52%
5 Years:	28%
3 Years:	98%
TTM:	30%

Stock Price CAGR
10 Years:	%
5 Years:	41%
3 Years:	-9%
1 Year:	-14%

Return on Equity
10 Years:	12%
5 Years:	11%
3 Years:	13%
Last Year:	14%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 1:41 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	2	2	2	2	2	3	4	4	4	4	5	5	5
Reserves	0	0	0	1	2	19	35	37	39	64	92	117	126
Borrowings	5	7	9	16	21	10	19	35	40	53	87	106	137
Other Liabilities	7	8	11	24	30	47	47	65	79	66	74	81	87
Total Liabilities	15	18	23	43	56	79	105	141	162	187	257	308	355
Fixed Assets	6	7	8	15	16	16	31	31	30	32	39	47	48
CWIP	0	0	1	0	4	11	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0	0	0	0	1	1
Other Assets	9	11	14	29	36	52	74	110	131	155	218	260	306
Total Assets	15	18	23	43	56	79	105	141	162	187	257	308	355

Below is a detailed analysis of the balance sheet data for Fredun Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹5.00 Cr..
For Reserves, as of Sep 2024, the value is ₹126.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹117.00 Cr. (Mar 2024) to ₹126.00 Cr., marking an increase of 9.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹137.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from ₹106.00 Cr. (Mar 2024) to ₹137.00 Cr., marking an increase of 31.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹87.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹81.00 Cr. (Mar 2024) to ₹87.00 Cr., marking an increase of 6.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹355.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹308.00 Cr. (Mar 2024) to ₹355.00 Cr., marking an increase of 47.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹48.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹47.00 Cr. (Mar 2024) to ₹48.00 Cr., marking an increase of 1.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹1.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹306.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹260.00 Cr. (Mar 2024) to ₹306.00 Cr., marking an increase of 46.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹355.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹308.00 Cr. (Mar 2024) to ₹355.00 Cr., marking an increase of 47.00 Cr..

However, the Borrowings (137.00 Cr.) are higher than the Reserves (₹126.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	1	-1	2	3	4	17	1	-11	0	-2	-14	-0
Cash from Investing Activity +	-1	-2	-3	-6	-7	-8	-5	-1	-1	-4	-9	-8
Cash from Financing Activity +	-0	2	1	3	3	-8	4	14	-1	7	25	6
Net Cash Flow	0	-0	0	1	-1	1	0	2	-2	1	1	-2

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-4.00	-6.00	-7.00	-12.00	-18.00	-4.00	-9.00	-27.00	-32.00	-39.00	-59.00	-68.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	47	59	75	98	131	94	67	126	112	148	46	68
Inventory Days	132	107	102	140	68	170	249	227	242	96	264	246
Days Payable	131	152	167	221	224	360	205	208	215	101	104	88
Cash Conversion Cycle	49	14	11	17	-24	-96	110	145	139	144	205	225
Working Capital Days	22	31	20	16	10	42	99	141	144	144	191	190
ROCE %	17%	14%	14%	25%	18%	16%	21%	10%	10%	13%	18%	17%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	51.27%	51.04%	51.04%	50.34%	50.15%	49.62%	49.31%	49.16%	49.17%	49.17%	48.93%	48.93%
DIIs	1.69%	1.68%	1.68%	1.66%	1.65%	1.64%	1.60%	1.60%	1.60%	1.60%	1.59%	1.59%
Public	47.04%	47.27%	47.27%	48.00%	48.20%	48.74%	49.08%	49.24%	49.24%	49.23%	49.47%	49.47%
No. of Shareholders	3,620	3,690	3,901	4,138	4,521	4,625	6,313	6,837	7,507	7,511	8,018	8,121

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	33.66	24.13	11.28	5.05	4.77
Diluted EPS (Rs.)	33.32	22.93	11.28	5.05	4.77
Cash EPS (Rs.)	41.32	30.04	19.16	10.07	9.48
Book Value[Excl.RevalReserv]/Share (Rs.)	258.49	212.64	153.54	107.96	103.57
Book Value[Incl.RevalReserv]/Share (Rs.)	258.49	212.64	153.54	107.96	103.57
Dividend / Share (Rs.)	0.70	0.70	0.70	0.70	0.66
Revenue From Operations / Share (Rs.)	740.88	606.04	506.38	335.60	282.66
PBDIT / Share (Rs.)	82.78	65.31	34.80	26.41	22.02
PBIT / Share (Rs.)	74.70	59.11	29.93	21.39	17.32
PBT / Share (Rs.)	45.65	38.63	19.40	8.04	6.25
Net Profit / Share (Rs.)	33.25	23.84	14.29	5.05	4.77
PBDIT Margin (%)	11.17	10.77	6.87	7.86	7.79
PBIT Margin (%)	10.08	9.75	5.91	6.37	6.12
PBT Margin (%)	6.16	6.37	3.83	2.39	2.21
Net Profit Margin (%)	4.48	3.93	2.82	1.50	1.68
Return on Networth / Equity (%)	12.86	11.21	9.30	4.67	4.60
Return on Capital Employeed (%)	24.93	17.72	11.71	11.35	12.47
Return On Assets (%)	5.07	4.20	3.38	1.24	1.42
Long Term Debt / Equity (X)	0.10	0.50	0.61	0.67	0.27
Total Debt / Equity (X)	0.86	0.89	0.77	0.92	0.84
Asset Turnover Ratio (%)	1.23	1.24	1.29	0.90	0.94
Current Ratio (X)	1.54	2.04	2.07	1.50	1.30
Quick Ratio (X)	0.49	0.62	1.44	0.72	0.65
Inventory Turnover Ratio (X)	1.75	2.51	3.11	1.71	1.88
Dividend Payout Ratio (NP) (%)	2.09	2.88	4.89	13.30	0.00
Dividend Payout Ratio (CP) (%)	1.68	2.28	3.65	6.67	0.00
Earning Retention Ratio (%)	97.91	97.12	95.11	86.70	0.00
Cash Earning Retention Ratio (%)	98.32	97.72	96.35	93.33	0.00
Interest Coverage Ratio (X)	2.85	3.19	3.30	2.53	1.99
Interest Coverage Ratio (Post Tax) (X)	2.14	2.16	2.36	1.76	1.43
Enterprise Value (Cr.)	441.23	435.36	456.41	223.45	78.34
EV / Net Operating Revenue (X)	1.27	1.59	2.03	1.67	0.69
EV / EBITDA (X)	11.34	14.71	29.59	21.21	8.92
MarketCap / Net Operating Revenue (X)	0.96	1.28	1.81	1.38	0.41
Retention Ratios (%)	97.90	97.11	95.10	86.69	0.00
Price / BV (X)	2.77	3.66	5.96	4.29	1.13
Price / Net Operating Revenue (X)	0.96	1.28	1.81	1.38	0.41
EarningsYield	0.04	0.03	0.01	0.01	0.04

After reviewing the key financial ratios for Fredun Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 33.66. This value is within the healthy range. It has increased from 24.13 (Mar 23) to 33.66, marking an increase of 9.53.
For Diluted EPS (Rs.), as of Mar 24, the value is 33.32. This value is within the healthy range. It has increased from 22.93 (Mar 23) to 33.32, marking an increase of 10.39.
For Cash EPS (Rs.), as of Mar 24, the value is 41.32. This value is within the healthy range. It has increased from 30.04 (Mar 23) to 41.32, marking an increase of 11.28.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 258.49. It has increased from 212.64 (Mar 23) to 258.49, marking an increase of 45.85.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 258.49. It has increased from 212.64 (Mar 23) to 258.49, marking an increase of 45.85.
For Dividend / Share (Rs.), as of Mar 24, the value is 0.70. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 23) which recorded 0.70.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 740.88. It has increased from 606.04 (Mar 23) to 740.88, marking an increase of 134.84.
For PBDIT / Share (Rs.), as of Mar 24, the value is 82.78. This value is within the healthy range. It has increased from 65.31 (Mar 23) to 82.78, marking an increase of 17.47.
For PBIT / Share (Rs.), as of Mar 24, the value is 74.70. This value is within the healthy range. It has increased from 59.11 (Mar 23) to 74.70, marking an increase of 15.59.
For PBT / Share (Rs.), as of Mar 24, the value is 45.65. This value is within the healthy range. It has increased from 38.63 (Mar 23) to 45.65, marking an increase of 7.02.
For Net Profit / Share (Rs.), as of Mar 24, the value is 33.25. This value is within the healthy range. It has increased from 23.84 (Mar 23) to 33.25, marking an increase of 9.41.
For PBDIT Margin (%), as of Mar 24, the value is 11.17. This value is within the healthy range. It has increased from 10.77 (Mar 23) to 11.17, marking an increase of 0.40.
For PBIT Margin (%), as of Mar 24, the value is 10.08. This value is within the healthy range. It has increased from 9.75 (Mar 23) to 10.08, marking an increase of 0.33.
For PBT Margin (%), as of Mar 24, the value is 6.16. This value is below the healthy minimum of 10. It has decreased from 6.37 (Mar 23) to 6.16, marking a decrease of 0.21.
For Net Profit Margin (%), as of Mar 24, the value is 4.48. This value is below the healthy minimum of 5. It has increased from 3.93 (Mar 23) to 4.48, marking an increase of 0.55.
For Return on Networth / Equity (%), as of Mar 24, the value is 12.86. This value is below the healthy minimum of 15. It has increased from 11.21 (Mar 23) to 12.86, marking an increase of 1.65.
For Return on Capital Employeed (%), as of Mar 24, the value is 24.93. This value is within the healthy range. It has increased from 17.72 (Mar 23) to 24.93, marking an increase of 7.21.
For Return On Assets (%), as of Mar 24, the value is 5.07. This value is within the healthy range. It has increased from 4.20 (Mar 23) to 5.07, marking an increase of 0.87.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 0.2. It has decreased from 0.50 (Mar 23) to 0.10, marking a decrease of 0.40.
For Total Debt / Equity (X), as of Mar 24, the value is 0.86. This value is within the healthy range. It has decreased from 0.89 (Mar 23) to 0.86, marking a decrease of 0.03.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.23. It has decreased from 1.24 (Mar 23) to 1.23, marking a decrease of 0.01.
For Current Ratio (X), as of Mar 24, the value is 1.54. This value is within the healthy range. It has decreased from 2.04 (Mar 23) to 1.54, marking a decrease of 0.50.
For Quick Ratio (X), as of Mar 24, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 23) to 0.49, marking a decrease of 0.13.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.75. This value is below the healthy minimum of 4. It has decreased from 2.51 (Mar 23) to 1.75, marking a decrease of 0.76.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 2.09. This value is below the healthy minimum of 20. It has decreased from 2.88 (Mar 23) to 2.09, marking a decrease of 0.79.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 1.68. This value is below the healthy minimum of 20. It has decreased from 2.28 (Mar 23) to 1.68, marking a decrease of 0.60.
For Earning Retention Ratio (%), as of Mar 24, the value is 97.91. This value exceeds the healthy maximum of 70. It has increased from 97.12 (Mar 23) to 97.91, marking an increase of 0.79.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 98.32. This value exceeds the healthy maximum of 70. It has increased from 97.72 (Mar 23) to 98.32, marking an increase of 0.60.
For Interest Coverage Ratio (X), as of Mar 24, the value is 2.85. This value is below the healthy minimum of 3. It has decreased from 3.19 (Mar 23) to 2.85, marking a decrease of 0.34.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.14. This value is below the healthy minimum of 3. It has decreased from 2.16 (Mar 23) to 2.14, marking a decrease of 0.02.
For Enterprise Value (Cr.), as of Mar 24, the value is 441.23. It has increased from 435.36 (Mar 23) to 441.23, marking an increase of 5.87.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.27. This value is within the healthy range. It has decreased from 1.59 (Mar 23) to 1.27, marking a decrease of 0.32.
For EV / EBITDA (X), as of Mar 24, the value is 11.34. This value is within the healthy range. It has decreased from 14.71 (Mar 23) to 11.34, marking a decrease of 3.37.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.96. This value is below the healthy minimum of 1. It has decreased from 1.28 (Mar 23) to 0.96, marking a decrease of 0.32.
For Retention Ratios (%), as of Mar 24, the value is 97.90. This value exceeds the healthy maximum of 70. It has increased from 97.11 (Mar 23) to 97.90, marking an increase of 0.79.
For Price / BV (X), as of Mar 24, the value is 2.77. This value is within the healthy range. It has decreased from 3.66 (Mar 23) to 2.77, marking a decrease of 0.89.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.96. This value is below the healthy minimum of 1. It has decreased from 1.28 (Mar 23) to 0.96, marking a decrease of 0.32.
For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 23) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Fredun Pharmaceuticals Ltd as of March 12, 2025 is: ₹536.08

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Fredun Pharmaceuticals Ltd is Overvalued by 20.46% compared to the current share price 674.00

Intrinsic Value of Fredun Pharmaceuticals Ltd as of March 12, 2025 is: 810.60

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Fredun Pharmaceuticals Ltd is Undervalued by 20.27% compared to the current share price 674.00

Last 5 Year EPS CAGR: 51.21%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 16.08%, which is a positive sign. The company has shown consistent growth in sales (139.69 cr) and profit (7.15 cr) over the years.	The stock has a high average Working Capital Days of 87.50, which may not be favorable. The stock has a high average Cash Conversion Cycle of 78.25, which may not be favorable. The company has higher borrowings (41.92) compared to reserves (40.92), which may suggest financial risk.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fredun Pharmaceuticals Ltd:
1. Net Profit Margin: 4.48%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 24.93% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 12.86% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 2.14
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.49
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 16.9 (Industry average Stock P/E: 42.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.86
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Fredun Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 08/06/1987 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1987PLC043662 and registration number is 043662. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 348.16 Cr. and Equity Capital is Rs. 4.70 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	URMI ESTATE, 11th Floor, Mumbai Maharashtra 400013	business@fredungroup.com http://www.fredungroup.com

Management
Name	Position Held
Dr.(Mrs.) Daulat N Medhora	Chairman & Jt. M. D
Mr. Fredun Medhora	Managing Director & CFO
Mr. Nariman Medhora	Non Executive Director
Dr. Rohinton Kanga	Ind. Non-Executive Director
Dr. Aspi Raimalwala	Ind. Non-Executive Director
Mrs. Daisy D�souza	Ind. Non-Executive Director

FAQ

What is the latest intrinsic value of Fredun Pharmaceuticals Ltd?

The latest intrinsic value of Fredun Pharmaceuticals Ltd as on 09 March 2025 is ₹536.08, which is 20.46% lower than the current market price of 674.00, indicating the stock is overvalued by 20.46%. The intrinsic value of Fredun Pharmaceuticals Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹318 Cr. and recorded a high/low of ₹1,024/635 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹126 Cr and total liabilities of ₹355 Cr.

What is the Market Cap of Fredun Pharmaceuticals Ltd?

The Market Cap of Fredun Pharmaceuticals Ltd is 318 Cr..

What is the current Stock Price of Fredun Pharmaceuticals Ltd as on 09 March 2025?

The current stock price of Fredun Pharmaceuticals Ltd as on 09 March 2025 is ₹674.

What is the High / Low of Fredun Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Fredun Pharmaceuticals Ltd stocks is ₹1,024/635.

What is the Stock P/E of Fredun Pharmaceuticals Ltd?

The Stock P/E of Fredun Pharmaceuticals Ltd is 16.9.

What is the Book Value of Fredun Pharmaceuticals Ltd?

The Book Value of Fredun Pharmaceuticals Ltd is 277.

What is the Dividend Yield of Fredun Pharmaceuticals Ltd?

The Dividend Yield of Fredun Pharmaceuticals Ltd is 0.10 %.

What is the ROCE of Fredun Pharmaceuticals Ltd?

The ROCE of Fredun Pharmaceuticals Ltd is 17.1 %.

What is the ROE of Fredun Pharmaceuticals Ltd?

The ROE of Fredun Pharmaceuticals Ltd is 14.3 %.

What is the Face Value of Fredun Pharmaceuticals Ltd?

The Face Value of Fredun Pharmaceuticals Ltd is 10.0.